A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: National Alliance for Research on Schizophrenia and Depression
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Subjects will be between 18-60

• Meet Diagnostic and Statistical Manual-IV (DSM) criteria for schizophrenia

• Be on a stable dose of antipsychotic medication for at least 1 month

• Be deemed clinically stable for 3 months by the regular clinical staff

Exclusion Criteria:

• Current substance or alcohol abuse

• Pregnancy

• Clozapine treatment

• Known sensitivity to sulphur containing compounds

• Previous diagnosis of mental retardation

• Nitroglycerin use

• Asthma diagnosis, verified and treated by a primary care doctor

• Use of any other medication that may interact with the study medication